Cost evaluation of basiliximab treatment for renal transplant patients in Japan

PharmacoEconomics

Volumn 21, Issue 11, 2003, Pages 791-806

  Hasegawa, Tomonori ^a   Imai, Hidehiko ^b   Miki, Sunao ^c  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MUSASHI UNIVERSITY   (Japan)

^c NOVARTIS PHARMA K K   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; METHYLPREDNISOLONE; OKT 3; PLACEBO;

ARTICLE; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DIALYSIS; DRUG COST; EVALUATION; EXPERIMENTAL MODEL; GRAFT REJECTION; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; JAPAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; PRIORITY JOURNAL; SIDE EFFECT; STEROID THERAPY; TREATMENT OUTCOME;

ADULT; AMBULATORY CARE; ANTIBODIES, MONOCLONAL; CYCLOSPORINE; DECISION TREES; DIRECT SERVICE COSTS; DRUG COSTS; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; KIDNEY TRANSPLANTATION; NEPHRECTOMY; PREDNISONE; RECOMBINANT FUSION PROTEINS; RENAL DIALYSIS; SENSITIVITY AND SPECIFICITY; TISSUE DONORS;

EID: 0041621852     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321110-00003     Document Type: Article

References (41)

1. Committee of Statistical Survey of the Japanese Society for Dialysis Therapy. An overview of dialysis treatment in Japan (as of Dec. 31, 1999) [in Japanese; abstract]. J Jpn Soc Dial Ther 2001; 34: 1
2. Annual Meeting of Japan Clinical Kidney Transplantation, The Japan Society for Transplantation. Report on the clinical registry of renal transplantation 1999 [in Japanese; abstract]. Jpn J Transplant 2000; 35: 43
3. Ohi G, Hasegawa T, Kumano H, et al. Why are cadaveric renal transplants so hard to find in Japan? Health Policy 1996; 6: 269-78
4. Annual Meeting of Japan Clinical Kidney Transplantation, The Japan Society for Transplantation. Report on the clinical registry of renal transplantation 1998 [in Japanese; abstract]. Jpn J Transplant 1999; 34: 51
5. Measures of dialysis and renal transplantation [in Japanese; abstract]. Jpn Med J 2000; 3961: 1
6. Suzuki M, Yoshida T, Yamazaki C. The third field study report on dialysis health expenditure [in Japanese; abstract]. J Jpn Clin Dial 2000; 15: 127
7. Committee of Public Relations of The Japan Society for Transplantation. Organ transplant facts book 2000 [in Japanese]. Osaka: The Japan Society for Transplantation, 2000 Oct
8. Sakamoto K, Iwai K. Cost of kidney transplantation and health care insurance [in Japanese; abstract]. Jpn J Dial Caring 1999; 5: 1268
9. Agishi T. Medical care using artificial organs and nursing: 4. Do artificial organs make humans happy? Comparison of organ transplantation and artificial organs: complementarity, prevalence, economical efficiency and QOL of artificial kidney and kidney transplantation [in Japanese; abstract]. Heart Nursing 1997; 10: 82
10. Yasumura T, Aikawa I, Ohmori Y, et al. Clinical factors correlated with 10-year graft survival of living related kidney transplantation III: acute rejection [in Japanese; abstract]. Jpn J Transplant 1992; 27: 375
11. Flechner SM, Modlin CS, Serrano DP, et al. Determinants of chronic renal allograft rejection in cyclosporine-treated recipients. Transplantation 1996; 62: 1235-41
12. Ferguson R. Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant 1994; 8: 328-31
13. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752-6
14. Ochiai T, Toma H, Takagi H, et al. The second report of a Japanese multi-center cooperative study for cyclosporin in renal transplantation [in Japanese; abstract]. Jpn J Transplant 1986; 21: 255
15. Ochiai T, Fukao K, Takahashi K, et al. A phase III comparative study of FK506 (tacrolimus) on kidney transplantation: comparison with cyclosporin-based immunosuppressant regimen [in Japanese; abstract]. Jpn J Transplant 1994; 29: 650
16. Lindholm A, Albrechtsen D, Flatmark A, et al. A randomized multicenter trial of cyclosporin and prednisolone versus cyclosporin, azathioprine, and prednisolone following primary living donor renal transplantation. Transpl Int 1994; 7: 207-15
17. Brinker KR, Dickerman RM, Gonwa TA, et al. A randomized trial comparing double-drug and triple-drug therapy in primary cadaveric renal transplants. Transplantation 1990; 50: 43-9
18. Niese D. A double-blind randomized study of Sandimmun Neoral versus Sandimmun in new renal transplant recipients: Results after 12 months. Transplant Proc 1995; 27: 1849-56
19. Lindholm A, Ohlman S, Albrechtsen D, et al. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 1993; 56: 307-15
20. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of FK 506/Prednisone vs FK 506/Azathioprine/Prednisone in renal transplant patients [abstract]. Transplant Proc 1995; 27: 814
21. Onrust SV, Wiseman LR. Basiliximab. Drugs 1999; 57: 207-13
22. Kovarik JM, Rawlings E, Sweny P, et al. Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI621 in renal allograft recipients. Transpl Int 1996; 9: S32-3
23. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193-8
24. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 1999; 67: 276-84
25. Keown PA, Balshaw R, Krueger H, et al. Economic analysis of basiliximab in renal transplantation. Transplantation 2001; 71: 1573-9
26. OECD Health Data 2000. A comparative analysis of 29 countries (database on CD ROM). Paris: OECD, 2000
27. Oka T. Presidential address: experiences of 480 cases of kidney transplantation [in Japanese; abstract]. J Jpn Surg Assoc 1997; 58: 713
28. Takahashi K, Kokado Y, Takahara S, et al. Immunosuppressive therapy. In: Takagi H, editor. Practices of cyclosporin [in Japanese]. Tokyo: Kokusai Igaku Shuppan Co Ltd, 1996: 57
29. Ota K. Immunosuppressive therapy for kidney transplantation [in Japanese; abstract]. Kidney Dialysis 1995; 39: 837
30. Sako H, Abe H, Shiraishi T, et al. Acute rejection in renal transplant recipients immunosuppressed with azathioprine or combination of azathioprine and ciclosporin [in Japanese; abstract]. Kidney Dialysis 1995; 38: 703
31. Sakai K, Hasegawa A. Organ transplantation and clinical test: tests necessary for transplantation: monitoring of rejection after kidney transplantation [in Japanese; abstract]. J Med Technol 1997; 41: 867
32. Takahashi K, Tanabe K, Tokumoto N, et al. Section 16: controlling outpatients. In: Takahashi K, Toma H, editors. Handbook of kidney transplantation [in Japanese]. Tokyo: Chugai Igakusha, 2000: 233
33. Tokumoto N, Nakagawa Y, Saito K, et al. Section 2: hospital visit, registration and examination. In: Takahashi K, Toma H, editors. Handbook of kidney transplantation [in Japanese]. Tokyo: Chugai Igakusha, 2000: 16
34. Saito T. Section 10: general control after transplantation. In: Takahashi K, Toma H, editors. Handbook of kidney transplantation [in Japanese]. Tokyo: Chugai Igakusha, 2000: 126
35. Noguchi N, Ikeda S, Sakamaki H, et al. Cost-effectiveness of RS-61443 (mycophenolate mofetil) treatment for intractable acute rejection in renal transplantation recipients [in Japanese; abstract]. J Health Care Soc 1998; 8: 41
36. Pirsch JD, Ploeg RJ, Gange S, et al. Determinants of graft survival after renal transplantation. Transplantation 1996; 61: 1581-6
37. Kawabuchi K. HCFA-DRG Cost analysis by division: example of Maryland [in Japanese]. In: The whole picture and issues of DRG/PP. Tokyo: Jiho, 1997: 173
38. Iritani Y, Omachi T, Sakakura T, et al. Clinical course of patients resuming dialysis after loss of a renal transplant [in Japanese; abstract]. J Jpn Soc Dialy Ther 1991; 24: 1373
39. Hirano T. Return to dialysis due to renal allograft rejection [in Japanese; abstract]. Jpn J Dialysis Caring 1996; Winter Suppl.: 156
40. Ponticelli C, Yussim A, Cambi V, et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001 Oct 15; 72 (7): 1261-7
41. Fujisawa M, Ichikawa Y, Yoshiya K, et al. Assessment of health-related quality of life in renal transplant and hemodialysis patients using the SF-36 health survey. Urology 2000; 56: 201-6